- Open
- 0.35
- High
- 0.40
- Low
- 0.30
- Close
- 0.30
- Change
- -0.05 (-14.29%)
- Volume
- 489,950
| 6 Jul 2026 | 07:00:11 | Investor presentation |
| 1 Jul 2026 | 11:22:02 | Holding(s) in Company |
| 29 Jun 2026 | 07:00:10 | Final results for the year ended 31 December 2025 |
| 25 Jun 2026 | 16:08:13 | Holding(s) in Company |
| 24 Jun 2026 | 17:24:30 | Holding(s) in Company |
| 20 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Verici Dx utilizes advanced sequencing technology to create a customized risk assessment for kidney transplant patients throughout their treatment, while also identifying potential damage earlier than traditional clinical and pathological methods.
Lord Stevens of Ludgate has interests in this issuer
| 6 Jul 2026 | 07:00:11 | Investor presentation |
| 1 Jul 2026 | 11:22:02 | Holding(s) in Company |
| 29 Jun 2026 | 07:00:10 | Final results for the year ended 31 December 2025 |
| 25 Jun 2026 | 16:08:13 | Holding(s) in Company |
| 24 Jun 2026 | 17:24:30 | Holding(s) in Company |
| 20 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Verici Dx utilizes advanced sequencing technology to create a customized risk assessment for kidney transplant patients throughout their treatment, while also identifying potential damage earlier than traditional clinical and pathological methods.
Lord Stevens of Ludgate has interests in this issuer